CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
Jianjun Chu1] Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA [2] The Ohio State University Comprehensive Cancer Center, Columbus, OH, USAYoucai Deng1] Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA [2] Institute of Materia Medica, College of Pharmacy, Third Military Medical University, Chongqing, PR ChinaD.M. Benson1] Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA [2] The Ohio State University Comprehensive Cancer Center, Columbus, OH, USAShun HeThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USATiffany HughesThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USAJian ZhangCenter for Biostatistics, The Ohio State University, Columbus, OH, USAYong PengThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USAHongyi MaoThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USALing YiThe Ohio State University Comprehensive Cancer Center, Columbus, OH, USAKalpana Ghoshal1] The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA [2] Department of Pathology, The Ohio State University, Columbus, OH, USAXiaoming He1] The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA [2] Department of Biomedical Engineering, The Ohio State University, Columbus, OH, USASteven M. Devine1] Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA [2] The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA [3] Blood and Marrow Transplantation Program, The James Cancer Hospital, The Ohio State University, Columbus, OH, USAXiaoliu ZhangDepartment of Biology and Biochemistry, Center for Nuclear Receptors and Cell Signaling, 3005 Science and Engineering Research Center, University of Houston, Houston, TX, USAMichael A. Caligiuri1] Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA [2] The Ohio State University Comprehensive Cancer Center, Columbus, OH, USACraig C. Hofmeister1] Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA [2] The Ohio State University Comprehensive Cancer Center, Columbus, OH, USAJianhua Yu1] Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA [2] The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA [3] Blood and Marrow Transplantation Program, The James Cancer Hospital, The Ohio State University, Columbus, OH, USA
2013en
ABI
Аннотация
Аннотация отсутствует.
Идентификаторы
Цитирования и источники
Цитирований: 3Использованных источников: 0